Final Results of a Randomized Controlled Study of the Ibritumomab Tiuxetan Radioimmunotherapy Regimen vs a Standard Course of Rituximab Immunotherapy for B-Cell Non-Hodgkin’s Lymphoma
ByT. E. Witzig,Christine A. White, MD,Leo I. Gordon, MD,J. L. Murray,G. A. Wiseman,C. Emmanouilides,Myron S. Czuczman, MD,D. Shen,Pratik S. Multani, MD,A. J. Grillo-Lopez, MD
Published: | Updated:
Ibritumomab tiuxetan (Zevalin) is a murine anti-CD20 monoclonal antibody covalently bound to the chelator tiuxetan, which can securely chelate yttrium-90. We performed a randomized controlled trial